Lipopeptides having pharmaceutical activity

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention describes a novel class of lipopeptide compounds, particularly glycosylated cyclic lipopeptides such as hassallidin A and B, which exhibit significant pharmaceutical activity. These compounds, isolated from cyanobacteria or synthesized, display broad antifungal effects, including against drug-resistant strains, and also show cytotoxicity against cancer cell lines. The patent covers both the compounds themselves and pharmaceutical compositions containing them, as well as methods for their production and isolation from specific cyanobacterial strains.

Use CasesContent extracted from patent full text and abstract with AI.

• Development of new antifungal drugs for treatment of invasive fungal infections, especially in immunocompromised patients (e.g., cancer, transplant, or AIDS patients).
• Potential treatment for fungal strains resistant to current antifungal therapies (e.g., Fusarium, Cryptococcus, Candida species, and Aspergillus).
• Development of anticancer agents based on the cytotoxic properties of these lipopeptides for chemotherapy or adjuvant cancer treatments.
• Pharmaceutical formulations combining these lipopeptides with other antifungal or anticancer agents for enhanced efficacy.
• Research tools for studying lipopeptide biosynthesis and modification in biotechnology or synthetic biology.

BenefitsContent extracted from patent full text and abstract with AI.

• Broader spectrum of antifungal activity compared to existing agents, effective even against fungal species that show resistance to current drugs.
• Higher bioavailability and the possibility of oral administration due to increased hydrophilicity conferred by glycosylation and hydroxylation.
• Potential for relatively low-cost and scalable production, as the source cyanobacteria are easy to cultivate.
• Activity against both fungal pathogens and cancer cell lines, providing a potential dual application in medicine.
• Improved pharmacological safety profile and reduced side effects compared to existing antifungal drugs, potentially resulting from novel structures and mechanisms of action.
• Easier chemical synthesis and modification due to known structural formulas, enabling optimization for efficacy or reduced toxicity.
• Ability to combine with other therapeutic agents for synergistic effects or to combat resistance.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to lipopeptides having pharmaceutical activity, to methods of their isolation and production, to pharmaceutical composition and uses thereof and to cyanobacteria from which the compounds may be isolated.